Home   Business   Article

Subscribe Now

Cambridge Clinical Laboratories becomes sole global lab partner for unique fertility test that aids IVF success




Cambridge Clinical Laboratories has become the only global laboratory partner for a first-of-its-kind fertility test that improves the chances of IVF success.

The Milton-based diagnostics lab is now offering the FSH receptor (FSH-R) polymorphism test by pMorph.

CSO Dr Tony Cooke, left, and CEO Jonathan Shrewsbury at Cambridge Clinical Laboratories
CSO Dr Tony Cooke, left, and CEO Jonathan Shrewsbury at Cambridge Clinical Laboratories

It can help doctors to tailor the stimulation treatment for each patient to maximise the chances of gaining eggs for IVF.

The simple PCR-based blood test examines the sequence of DNA involved in recognising and responding to FSH, or follicle stimulating hormone. This is the hormone responsible for the recruitment and development of eggs within the ovaries.

Doctors prescribe drugs containing FSH to IVF patients in order to stimulate the ovaries to produce numerous eggs

By identifying the sensitivity of receptors in the patient’s ovaries, the FSH-R polymorphism test is able to indicate how the patient may respond to IVF treatment, which will help clinicians decide on the right dose and type of stimulation to achieve a good number of eggs.

The information cannot be gathered in any other way.

CSO Dr Tony Cooke, left, and CEO Jonathan Shrewsbury at Cambridge Clinical Laboratories
CSO Dr Tony Cooke, left, and CEO Jonathan Shrewsbury at Cambridge Clinical Laboratories

CCL CEO Jonathan Shrewsbury says: “At CCL we look to offer the most innovative, state-of- the-art personalised medicine tests to the UK market, and abroad. Our work enables healthcare professionals to provide the most effective clinical outcomes for their patients.

“The FSHR Polymorphism fertility test, by pMorph Genetic Testing, is our first step into supporting development in the fertility field. We’re incredibly excited to support this being made available to a global market.”

It is the only United Kingdom Accreditation Service (UKAS) approved test for pharmacogenomics in fertility and satisfies Human Fertilisation and Embryology Authority (HFEA) licence requirements.

Jonathan adds: “We are living in revolutionary times with regards to personalised healthcare diagnostics and specifically targeted therapeutics, and we plan for CCL to be at the forefront of that revolution.”

Visit camclinlabs.co.uk/fertility and www.pmorph.com for details.



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More